Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Multiple Sclerosis

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 463 articles:
HTML format



Single Articles


    January 2023
  1. CHIA NH, Redenbaugh V, Chen JJ, Pittock SJ, et al
    Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis.
    Mult Scler. 2023 Jan 24:13524585221150743. doi: 10.1177/13524585221150743.
    PubMed     Abstract available


  2. HU C, Dewey BE, Mowry EM, Fitzgerald KC, et al
    Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort.
    Mult Scler. 2023 Jan 24:13524585221148144. doi: 10.1177/13524585221148144.
    PubMed     Abstract available


  3. SADOVNICK D, Criscuoli M, Yee I, Carruthers R, et al
    The Canadian Multiple Sclerosis Pregnancy Study: First-trimester miscarriages in women with multiple sclerosis.
    Mult Scler. 2023 Jan 22:13524585221146270. doi: 10.1177/13524585221146270.
    PubMed     Abstract available


  4. ABBADESSA G, Miele G, Maida E, Vanore E, et al
    Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis.
    Mult Scler. 2023 Jan 22:13524585221147635. doi: 10.1177/13524585221147635.
    PubMed     Abstract available


  5. O'MAHONY J, Banwell B, Laporte A, Brown A, et al
    Family health conditions and parental occupational status modify the relationship between pediatric-onset multiple sclerosis and parental health-related quality of life.
    Mult Scler. 2023 Jan 19:13524585221144413. doi: 10.1177/13524585221144413.
    PubMed     Abstract available


  6. ANDERSON J, Sumowski JF
    Towards a phenotypic understanding of multiple sclerosis depression.
    Mult Scler. 2023 Jan 12:13524585221148143. doi: 10.1177/13524585221148143.
    PubMed    


  7. BRALEY TJ, Shieu MM, Zaheed AB, Dunietz GL, et al
    Pathways between multiple sclerosis, sleep disorders, and cognitive function: Longitudinal findings from The Nurses' Health Study.
    Mult Scler. 2023 Jan 12:13524585221144215. doi: 10.1177/13524585221144215.
    PubMed     Abstract available


    December 2022
  8. BLOCK VJ, Cheng S, Juwono J, Cuneo R, et al
    Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis.
    Mult Scler. 2022 Dec 27:13524585221143726. doi: 10.1177/13524585221143726.
    PubMed     Abstract available


  9. FOX RJ, Tervonen T, Phillips-Beyer A, Sidorenko T, et al
    The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
    Mult Scler. 2022 Dec 22:13524585221140270. doi: 10.1177/13524585221140270.
    PubMed     Abstract available


  10. TSAGKAS C, Huck-Horvath A, Cagol A, Haas T, et al
    Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
    Mult Scler. 2022 Dec 22:13524585221139152. doi: 10.1177/13524585221139152.
    PubMed     Abstract available


  11. JAKIMOVSKI D, Kavak KS, Zakalik K, Coetzee T, et al
    Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC).
    Mult Scler. 2022 Dec 22:13524585221140271. doi: 10.1177/13524585221140271.
    PubMed     Abstract available


  12. LONGONI G, Martinez Chavez E, Young K, Brown RA, et al
    Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis.
    Mult Scler. 2022 Dec 22:13524585221137500. doi: 10.1177/13524585221137500.
    PubMed     Abstract available


  13. KRAJNC N, Dal-Bianco A, Leutmezer F, Kasprian G, et al
    Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis.
    Mult Scler. 2022 Dec 20:13524585221138486. doi: 10.1177/13524585221138486.
    PubMed     Abstract available


  14. HEGEN H, Arrambide G, Gnanapavan S, Kaplan B, et al
    Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.
    Mult Scler. 2022 Dec 17:13524585221134217. doi: 10.1177/13524585221134217.
    PubMed     Abstract available


  15. CALVI A, Clarke MA, Prados F, Chard D, et al
    Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis.
    Mult Scler. 2022 Dec 14:13524585221141964. doi: 10.1177/13524585221141964.
    PubMed     Abstract available


  16. SABATHE C, Casey R, Vukusic S, Leray E, et al
    Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
    Mult Scler. 2022 Dec 14:13524585221139156. doi: 10.1177/13524585221139156.
    PubMed     Abstract available


  17. DE MEO E, Portaccio E
    It is time to define cognitive phenotypes in multiple sclerosis.
    Mult Scler. 2022 Dec 14:13524585221141263. doi: 10.1177/13524585221141263.
    PubMed    


  18. JOKUBAITIS VG
    A role for HLA in mediating long-term multiple sclerosis outcomes?
    Mult Scler. 2022 Dec 14:13524585221139767. doi: 10.1177/13524585221139767.
    PubMed    


  19. BOCCIA VD, Lapucci C, Cellerino M, Tazza F, et al
    Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study.
    Mult Scler. 2022 Dec 13:13524585221142319. doi: 10.1177/13524585221142319.
    PubMed     Abstract available


  20. ABDEL-MANNAN O, Ciccarelli O
    Is the central vein sign a useful diagnostic marker for paediatric-onset multiple sclerosis?
    Mult Scler. 2022 Dec 13:13524585221142318. doi: 10.1177/13524585221142318.
    PubMed    


  21. OKUDA DT, Stanley T, McCreary M, Smith A, et al
    Selective vulnerability of brainstem and cervical spinal cord regions in people with non-progressive multiple sclerosis of Black or African American and European ancestry.
    Mult Scler. 2022 Dec 12:13524585221139575. doi: 10.1177/13524585221139575.
    PubMed     Abstract available


  22. HEGEN H, Walde J, Berek K, Arrambide G, et al
    Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis.
    Mult Scler. 2022 Dec 1:13524585221134213. doi: 10.1177/13524585221134213.
    PubMed     Abstract available


    November 2022
  23. MOTTE J, Gold R
    Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis.
    Mult Scler. 2022 Nov 30:13524585221137275. doi: 10.1177/13524585221137275.
    PubMed    


  24. BARRITT AW, Das E, Morley N, Seymour M, et al
    Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
    Mult Scler. 2022 Nov 30:13524585221137279. doi: 10.1177/13524585221137279.
    PubMed     Abstract available


  25. MORADI N, Sharmin S, Malpas CB, Shaygannejad V, et al
    External validation of a clinical prediction model in multiple sclerosis.
    Mult Scler. 2022 Nov 30:13524585221136036. doi: 10.1177/13524585221136036.
    PubMed     Abstract available



  26. Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Mult Scler. 2022 Nov 30:13524585221138507. doi: 10.1177/13524585221138507.
    PubMed    


  27. BARRO C, Healy BC, Saxena S, Glanz BI, et al
    Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients.
    Mult Scler. 2022 Nov 30:13524585221137697. doi: 10.1177/13524585221137697.
    PubMed     Abstract available


  28. REDER AT, Stuve O, Tankou SK, Leist TP, et al
    T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.
    Mult Scler. 2022 Nov 28:13524585221134216. doi: 10.1177/13524585221134216.
    PubMed     Abstract available


  29. SPELMAN T, Ozakbas S, Alroughani R, Terzi M, et al
    Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Mult Scler. 2022 Nov 26:13524585221137502. doi: 10.1177/13524585221137502.
    PubMed     Abstract available


  30. BROWNLEE WJ, Tur C, Manole A, Eshaghi A, et al
    HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis.
    Mult Scler. 2022 Nov 18:13524585221130941. doi: 10.1177/13524585221130941.
    PubMed     Abstract available


  31. FOLEY J, Xiong K, Hoyt T, Singh CM, et al
    Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice.
    Mult Scler. 2022 Nov 15:13524585221130949. doi: 10.1177/13524585221130949.
    PubMed     Abstract available


  32. VUKUSIC S, Marignier R, Ciron J, Bourre B, et al
    Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.
    Mult Scler. 2022 Nov 8:13524585221130934. doi: 10.1177/13524585221130934.
    PubMed     Abstract available


  33. BROWNLEE WJ
    Cladribine-induced liver injury: Implications for practice.
    Mult Scler. 2022;28:2146.
    PubMed    


  34. CAMARA-LEMARROY C, Metz L, Kuhle J, Leppert D, et al
    Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.
    Mult Scler. 2022;28:2081-2089.
    PubMed     Abstract available


  35. VUKUSIC S, Carra-Dalliere C, Ciron J, Maillart E, et al
    Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
    Mult Scler. 2022 Nov 1:13524585221129472. doi: 10.1177/13524585221129472.
    PubMed     Abstract available


    October 2022
  36. CHERTCOFF A, Ng HS, Zhu F, Zhao Y, et al
    Polypharmacy and multiple sclerosis: A population-based study.
    Mult Scler. 2022 Oct 27:13524585221122207. doi: 10.1177/13524585221122207.
    PubMed     Abstract available


  37. CALOCER F, Ng HS, Zhu F, Zhao Y, et al
    Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis.
    Mult Scler. 2022 Oct 25:13524585221129963. doi: 10.1177/13524585221129963.
    PubMed     Abstract available


  38. DOST-KOVALSKY K, Thiel S, Ciplea AI, Gold R, et al
    Cladribine and pregnancy in women with multiple sclerosis: The first cohort study.
    Mult Scler. 2022 Oct 22:13524585221131486. doi: 10.1177/13524585221131486.
    PubMed     Abstract available


  39. CARDENAS-ROBLEDO S, Gonzalez-Caicedo P, Carvajal-Parra MS, Guio-Sanchez CM, et al
    No seasonality in the risk of multiple sclerosis in an equatorial country: A case-control ecological study.
    Mult Scler. 2022 Oct 15:13524585221130020. doi: 10.1177/13524585221130020.
    PubMed     Abstract available


  40. BOURDETTE D, Herink M
    Polypharmacy in multiple sclerosis: More is not necessarily better.
    Mult Scler. 2022 Oct 14:13524585221129964. doi: 10.1177/13524585221129964.
    PubMed    


  41. HANCOCK LM, Galioto R, Samsonov A, Busch RM, et al
    A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS).
    Mult Scler. 2022 Oct 14:13524585221127941. doi: 10.1177/13524585221127941.
    PubMed     Abstract available


  42. KATZ SAND I, Levy S, Fitzgerald K, Sorets T, et al
    Mediterranean diet is linked to less objective disability in multiple sclerosis.
    Mult Scler. 2022 Oct 13:13524585221127414. doi: 10.1177/13524585221127414.
    PubMed     Abstract available


  43. HUISKAMP M, Kiljan S, Kulik S, Witte ME, et al
    Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study.
    Mult Scler. 2022 Oct 3:13524585221125381. doi: 10.1177/13524585221125381.
    PubMed     Abstract available


  44. PAUWELS A, Van Schependom J, Devolder L, Van Remoortel A, et al
    Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Mult Scler. 2022;28:1685-1696.
    PubMed     Abstract available


  45. FORD CC, Cohen JA, Goodman AD, Lindsey JW, et al
    Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
    Mult Scler. 2022;28:1729-1743.
    PubMed     Abstract available


  46. HARDY TA, Guo Y, Flanagan EP, Lucchinetti CF, et al
    The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions.
    Mult Scler. 2022;28:1710-1718.
    PubMed     Abstract available


  47. CAPANNA M, Signori A, Sormani MP
    Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials.
    Mult Scler. 2022;28:1744-1751.
    PubMed     Abstract available


  48. ZARGHAMI A, van der Mei I, Hussain MA, Claflin SB, et al
    Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination.
    Mult Scler. 2022;28:1793-1807.
    PubMed     Abstract available


  49. GRAF J, Ng HS, Zhu F, Zhao Y, et al
    Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits.
    Mult Scler. 2022;28:1825-1828.
    PubMed     Abstract available


  50. GAETANI L, Schoonheim MM
    Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures.
    Mult Scler. 2022;28:1831-1833.
    PubMed    


  51. KOUBIYR I, Broeders TA, Deloire M, Brochet B, et al
    Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome.
    Mult Scler. 2022;28:1973-1982.
    PubMed     Abstract available


  52. ARNOLD DL, Sprenger T, Bar-Or A, Wolinsky JS, et al
    Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
    Mult Scler. 2022;28:1927-1936.
    PubMed     Abstract available


  53. BESSING B, Claflin SB, Taylor BV, Blizzard L, et al
    Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss.
    Mult Scler. 2022;28:1983-1996.
    PubMed     Abstract available



  54. ECTRIMS 2022 Committees.
    Mult Scler. 2022;28.
    PubMed    


    September 2022
  55. BUHLER A, Wolbers M, Model F, Wang Q, et al
    Recurrent disability progression endpoints in multiple sclerosis clinical trials.
    Mult Scler. 2022 Sep 30:13524585221125382. doi: 10.1177/13524585221125382.
    PubMed     Abstract available


  56. ALEXANDER S, Braisher M, Tur C, Chataway J, et al
    The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis.
    Mult Scler. 2022 Sep 30:13524585221124043. doi: 10.1177/13524585221124043.
    PubMed     Abstract available


  57. STRIK M, Eijlers AJ, Dekker I, Broeders TA, et al
    Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis.
    Mult Scler. 2022 Sep 30:13524585221125372. doi: 10.1177/13524585221125372.
    PubMed     Abstract available


  58. SARACENO L, Pirro F, Stigliano R, Agostoni EC, et al
    Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders.
    Mult Scler. 2022 Sep 28:13524585221125360. doi: 10.1177/13524585221125360.
    PubMed     Abstract available


  59. BRUIJSTENS AL, Stingl C, Guzel C, Stoop MP, et al
    Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood.
    Mult Scler. 2022 Sep 24:13524585221125369. doi: 10.1177/13524585221125369.
    PubMed     Abstract available


  60. POL-PATIL J, Glanz B, Safar L, Misasi E, et al
    MeTooMS: Sexual, physical, and emotional abuse experience among women with multiple sclerosis.
    Mult Scler. 2022 Sep 24:13524585221122169. doi: 10.1177/13524585221122169.
    PubMed     Abstract available


  61. CHANG I, Kappos L, Giovannoni G, Calabresi PA, et al
    Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
    Mult Scler. 2022 Sep 21:13524585221114997. doi: 10.1177/13524585221114997.
    PubMed     Abstract available


  62. COHEN JA, Lublin FD, Lock C, Pelletier D, et al
    Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
    Mult Scler. 2022 Sep 14:13524585221122156. doi: 10.1177/13524585221122156.
    PubMed     Abstract available


  63. VAN LIEROP ZY, Noteboom S, Steenwijk MD, van Dam M, et al
    Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
    Mult Scler. 2022 Sep 3:13524585221118676. doi: 10.1177/13524585221118676.
    PubMed     Abstract available


  64. MCGINLEY MP, Lapin B
    The value of patient-reported outcome measures for multiple sclerosis.
    Mult Scler. 2022;28:1489-1490.
    PubMed    


  65. STRIJBIS EM, Repovic P, Mostert J, Bowen JD, et al
    The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
    Mult Scler. 2022;28:1606-1619.
    PubMed     Abstract available


  66. KLISTORNER S, Barnett MH, Graham SL, Wang C, et al
    The expansion and severity of chronic MS lesions follows a periventricular gradient.
    Mult Scler. 2022;28:1504-1514.
    PubMed     Abstract available


  67. XIANG B, Brier MR, Kanthamneni M, Wen J, et al
    Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Mult Scler. 2022;28:1515-1525.
    PubMed     Abstract available


  68. THEBAULT S, Bose G, Booth R, Freedman MS, et al
    Serum neurofilament light in MS: The first true blood-based biomarker?
    Mult Scler. 2022;28:1491-1497.
    PubMed     Abstract available


  69. PORTACCIO E, Amato MP
    Reliable change indices for cognitive assessment of patients with multiple sclerosis.
    Mult Scler. 2022 Sep 1:13524585221116273. doi: 10.1177/13524585221116273.
    PubMed    


    August 2022
  70. MEATON I, Altokhis A, Allen CM, Clarke MA, et al
    Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
    Mult Scler. 2022 Aug 26:13524585221118677. doi: 10.1177/13524585221118677.
    PubMed     Abstract available


  71. BROWNLEE WJ, Wolf C, Hartung HP, Dingermann T, et al
    Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
    Mult Scler. 2022 Aug 24:13524585221116269. doi: 10.1177/13524585221116269.
    PubMed     Abstract available


  72. ALTOKHIS AI, Hibbert AM, Allen CM, Mougin O, et al
    Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis.
    Mult Scler. 2022 Aug 24:13524585221114750. doi: 10.1177/13524585221114750.
    PubMed     Abstract available


  73. YOUNG CA, Mills RJ, Langdon D, Rog DJ, et al
    Measuring coping in multiple sclerosis: The Coping Index-MS.
    Mult Scler. 2022 Aug 24:13524585221114004. doi: 10.1177/13524585221114004.
    PubMed     Abstract available


  74. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
    Mult Scler. 2022 Aug 15:13524585221114007. doi: 10.1177/13524585221114007.
    PubMed     Abstract available


  75. BLYAU S, Koubiyr I, Saranathan M, Coupe P, et al
    Differential vulnerability of thalamic nuclei in multiple sclerosis.
    Mult Scler. 2022 Aug 12:13524585221114247. doi: 10.1177/13524585221114247.
    PubMed     Abstract available


  76. CONWAY SE, Pua DKA, Holroyd KB, Galetta K, et al
    Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors.
    Mult Scler. 2022 Aug 11:13524585221117949. doi: 10.1177/13524585221117949.
    PubMed     Abstract available


  77. WILLIAMS T, Tur C, Eshaghi A, Doshi A, et al
    Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial.
    Mult Scler. 2022 Aug 9:13524585221114441. doi: 10.1177/13524585221114441.
    PubMed     Abstract available


  78. CIFTCI KAVAKLIOGLU B, Erdman L, Goldenberg A, Kavaklioglu C, et al
    Machine learning classification of multiple sclerosis in children using optical coherence tomography.
    Mult Scler. 2022 Aug 9:13524585221112605. doi: 10.1177/13524585221112605.
    PubMed     Abstract available


  79. UCCELLI A, Freedman MS
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No.
    Mult Scler. 2022;28:1326-1328.
    PubMed    


  80. PERUZZOTTI-JAMETTI L, Pluchino S
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary.
    Mult Scler. 2022;28:1328-1329.
    PubMed    


  81. KARUSSIS D, Kassis I, Petrou P
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES.
    Mult Scler. 2022;28:1324-1326.
    PubMed    


  82. SESEL AL, Sharpe L, Beadnall HN, Barnett MH, et al
    A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression.
    Mult Scler. 2022;28:1392-1401.
    PubMed     Abstract available


    July 2022
  83. TAGGE IJ, Leppert IR, Fetco D, Campbell JS, et al
    Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
    Mult Scler. 2022 Jul 28:13524585221110585. doi: 10.1177/13524585221110585.
    PubMed     Abstract available


  84. ZHONG M, van der Walt A, Monif M, Hodgkinson S, et al
    Prediction of relapse activity when switching to cladribine for multiple sclerosis.
    Mult Scler. 2022 Jul 27:13524585221111677. doi: 10.1177/13524585221111677.
    PubMed     Abstract available


  85. KLISTORNER S, Barnett MH, Klistorner A
    Mechanisms of central brain atrophy in multiple sclerosis.
    Mult Scler. 2022 Jul 21:13524585221111684. doi: 10.1177/13524585221111684.
    PubMed     Abstract available


  86. JOHNSSON M, Farman HH, Blennow K, Zetterberg H, et al
    No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Mult Scler. 2022 Jul 20:13524585221108080. doi: 10.1177/13524585221108080.
    PubMed     Abstract available


  87. MAGYARI M, Joensen H, Kopp TI, Pontieri L, et al
    Changes in prognosis of the Danish multiple sclerosis population over time.
    Mult Scler. 2022 Jul 13:13524585221110582. doi: 10.1177/13524585221110582.
    PubMed     Abstract available


  88. KRIEGER SC, Antoine A, Sumowski JF
    EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold.
    Mult Scler. 2022 Jul 13:13524585221108297. doi: 10.1177/13524585221108297.
    PubMed     Abstract available


  89. ANNA KARIN H, Erik S, Tim S, Lars F, et al
    The impact of bariatric surgery on disease activity and progression of multiple sclerosis: A nationwide matched cohort study.
    Mult Scler. 2022 Jul 7:13524585221107095. doi: 10.1177/13524585221107095.
    PubMed     Abstract available


  90. LADAKIS DC, Yao PJ, Vreones M, Blommer J, et al
    Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis.
    Mult Scler. 2022 Jul 5:13524585221106290. doi: 10.1177/13524585221106290.
    PubMed     Abstract available


  91. MANUEL ESCOBAR J, Cortese M, Edan G, Freedman MS, et al
    Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
    Mult Scler. 2022;28:1277-1285.
    PubMed     Abstract available


  92. W KOCH M, Mostert J, Repovic P, Bowen JD, et al
    Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
    Mult Scler. 2022;28:1286-1298.
    PubMed     Abstract available


  93. ANDERSEN JB, Wandall-Holm MF, Andersen PK, Sellebjerg F, et al
    Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort.
    Mult Scler. 2022;28:1239-1247.
    PubMed     Abstract available


  94. GIOVANNONI G, Singer BA, Issard D, Jack D, et al
    Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
    Mult Scler. 2022;28:1219-1228.
    PubMed     Abstract available


  95. EISELE P, Wittayer M, Weber CE, Platten M, et al
    Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions.
    Mult Scler. 2022 Jul 1:13524585221106338. doi: 10.1177/13524585221106338.
    PubMed     Abstract available


    June 2022
  96. PROUSKAS SE, Schoonheim MM, Huiskamp M, Steenwijk MD, et al
    A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?
    Mult Scler. 2022 Jun 28:13524585221103134. doi: 10.1177/13524585221103134.
    PubMed     Abstract available


  97. CREE BA, Selmaj KW, Steinman L, Comi G, et al
    Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584.
    PubMed     Abstract available


  98. MARASTONI D, Crescenzo F, Pisani AI, Zuco C, et al
    Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
    Mult Scler. 2022 Jun 28:13524585221104014. doi: 10.1177/13524585221104014.
    PubMed     Abstract available


  99. MAGNE F, Cellerino M, Balletto E, Aluan K, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.
    PubMed    


  100. HEMOND CC, Baek J, Ionete C, Reich DS, et al
    Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study.
    Mult Scler. 2022 Jun 24:13524585221102921. doi: 10.1177/13524585221102921.
    PubMed     Abstract available


  101. GARJANI A, Liu BJ, Allen CM, Gunzler DD, et al
    Decentralised clinical trials in multiple sclerosis research.
    Mult Scler. 2022 Jun 23:13524585221100401. doi: 10.1177/13524585221100401.
    PubMed     Abstract available


  102. SCHIAVETTI I, Cordioli C, Stromillo ML, Teresa Ferro M, et al
    Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
    Mult Scler. 2022 Jun 23:13524585221102918. doi: 10.1177/13524585221102918.
    PubMed     Abstract available


  103. MAAROUF A, Audoin B, Gherib S, El Mendili MM, et al
    Grey-matter sodium concentration as an individual marker of multiple sclerosis severity.
    Mult Scler. 2022 Jun 20:13524585221102587. doi: 10.1177/13524585221102587.
    PubMed     Abstract available


  104. LAZZAROTTO A, Tonietto M, Poirion E, Battaglini M, et al
    Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: A multimodal and multicompartment imaging study.
    Mult Scler. 2022 Jun 16:13524585221096975. doi: 10.1177/13524585221096975.
    PubMed     Abstract available


  105. CHO EB, Yeo Y, Jung JH, Jeong SM, et al
    Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
    Mult Scler. 2022 Jun 13:13524585221096964. doi: 10.1177/13524585221096964.
    PubMed     Abstract available


  106. AL-LOUZI O, Manukyan S, Donadieu M, Absinta M, et al
    Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study.
    Mult Scler. 2022 Jun 8:13524585221097560. doi: 10.1177/13524585221097560.
    PubMed     Abstract available


  107. SCHMIERER K, Wiendl H, Oreja-Guevara C, Centonze D, et al
    Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
    Mult Scler. 2022 Jun 7:13524585221099413. doi: 10.1177/13524585221099413.
    PubMed    


  108. BRUNE S, Hogestol EA, de Rodez Benavent SA, Berg-Hansen P, et al
    Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221097296. doi: 10.1177/13524585221097296.
    PubMed     Abstract available


  109. LEAVITT VM, Dworkin JD, Buyukturkoglu K, Riley CS, et al
    Summary metrics of memory subnetwork functional connectivity alterations in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221099169. doi: 10.1177/13524585221099169.
    PubMed     Abstract available


  110. BEREK K, Hegen H, Hocher J, Auer M, et al
    Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.
    Mult Scler. 2022 Jun 2:13524585221097566. doi: 10.1177/13524585221097566.
    PubMed     Abstract available


  111. CARCAMO C, Ciampi E
    Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary.
    Mult Scler. 2022;28:1032-1033.
    PubMed    


  112. PIEHL F, Mathew T
    Low-dose rituximab should be used for treating MS in resource-limited settings: Yes.
    Mult Scler. 2022;28:1028-1029.
    PubMed    


  113. MATEEN FJ
    Low-dose rituximab should be used for treating MS in resource-limited settings: No.
    Mult Scler. 2022;28:1030-1032.
    PubMed    


  114. PODDA J, Tacchino A, Pedulla L, Monti Bragadin M, et al
    Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.
    Mult Scler. 2022;28:1009-1019.
    PubMed     Abstract available


    May 2022
  115. COFRE LIZAMA LE, Strik M, Van der Walt A, Kilpatrick TJ, et al
    Gait stability reflects motor tracts damage at early stages of multiple sclerosis.
    Mult Scler. 2022 May 21:13524585221094464. doi: 10.1177/13524585221094464.
    PubMed     Abstract available


  116. FADDA G, Waters P, Woodhall M, Brown RA, et al
    Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.
    Mult Scler. 2022 May 17:13524585221093789. doi: 10.1177/13524585221093789.
    PubMed     Abstract available


  117. GONZALEZ-MARTINEZ A, Bose G, Chitnis T
    Anti-CGRP therapies for migraine in multiple sclerosis patients.
    Mult Scler. 2022 May 14:13524585221096353. doi: 10.1177/13524585221096353.
    PubMed    


  118. SCHWARZ T, Otto C, Jones TC, Pache F, et al
    Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
    Mult Scler. 2022 May 14:13524585221094478. doi: 10.1177/13524585221094478.
    PubMed     Abstract available


  119. LEUNG MW, Bazelier MT, Souverein PC, Uitdehaag BM, et al
    Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.
    Mult Scler. 2022 May 14:13524585221094218. doi: 10.1177/13524585221094218.
    PubMed     Abstract available


  120. ALMRAMHI MM, Storm CS, Kia DA, Coneys R, et al
    The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study.
    Mult Scler. 2022 May 14:13524585221092644. doi: 10.1177/13524585221092644.
    PubMed     Abstract available


  121. CHIARAVALLOTI ND, DeLuca J, Salter A, Amato MP, et al
    The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.
    Mult Scler. 2022 May 9:13524585221088190. doi: 10.1177/13524585221088190.
    PubMed     Abstract available


  122. MANGLANI HR, Fisher ME, Duraney EJ, Nicholas JA, et al
    A promising cognitive screener in multiple sclerosis: The NIH toolbox cognition battery concords with gold standard neuropsychological measures.
    Mult Scler. 2022 May 9:13524585221088731. doi: 10.1177/13524585221088731.
    PubMed     Abstract available


  123. VALSASINA P, Gobbi C, Zecca C, Rovira A, et al
    Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis.
    Mult Scler. 2022;28:885-899.
    PubMed     Abstract available


  124. ROSENSTEIN I, Axelsson M, Novakova L, Blennow K, et al
    Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
    Mult Scler. 2022;28:872-884.
    PubMed     Abstract available



  125. ACTRIMS Forum 2022.
    Mult Scler. 2022;28.
    PubMed    


    April 2022
  126. SPRENGER T, Kappos L, Sormani MP, Miller AE, et al
    Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
    Mult Scler. 2022 Apr 29:13524585221089534. doi: 10.1177/13524585221089534.
    PubMed     Abstract available


  127. DEGRAEVE B, Sequeira H, Mecheri H, Lenne B, et al
    Corpus callosum damage to account for cognitive, affective, and social-cognitive dysfunctions in multiple sclerosis: A model of callosal disconnection syndrome?
    Mult Scler. 2022 Apr 27:13524585221091067. doi: 10.1177/13524585221091067.
    PubMed     Abstract available


  128. MANZANO GS, Rice DR, Klawiter EC, Matiello M, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Apr 27:13524585221092309. doi: 10.1177/13524585221092309.
    PubMed     Abstract available


  129. ZABALZA A, Arrambide G, Otero-Romero S, Pappolla A, et al
    Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
    Mult Scler. 2022 Apr 27:13524585221089540. doi: 10.1177/13524585221089540.
    PubMed     Abstract available


  130. SIMONEAU G, Pellegrini F, Debray TP, Rouette J, et al
    Recommendations for the use of propensity score methods in multiple sclerosis research.
    Mult Scler. 2022 Apr 6:13524585221085733. doi: 10.1177/13524585221085733.
    PubMed     Abstract available


  131. CREE BA, Arnold DL, Fox RJ, Gold R, et al
    Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Mult Scler. 2022 Apr 5:13524585221083194. doi: 10.1177/13524585221083194.
    PubMed     Abstract available


  132. KALINCIK T, Kister I, Bacon TE, Malpas CB, et al
    Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
    Mult Scler. 2022 Apr 3:13524585221084577. doi: 10.1177/13524585221084577.
    PubMed     Abstract available


  133. MOCCIA M, Affinito G, Ronga B, Giordana R, et al
    Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).
    Mult Scler. 2022;28:597-607.
    PubMed     Abstract available


  134. GRATCH D, Zhovtis Ryerson L
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary.
    Mult Scler. 2022;28:695-696.
    PubMed    


  135. INES CIPLEA A, Kurzeja A, Thiel S, Haben S, et al
    Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.
    Mult Scler. 2022 Apr 1:13524585221083982. doi: 10.1177/13524585221083982.
    PubMed     Abstract available


  136. TZANETAKOS D, Tzartos JS, Vakrakou AG, Breza M, et al
    Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study.
    Mult Scler. 2022;28:718-729.
    PubMed     Abstract available


  137. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter.
    Mult Scler. 2022;28:697-706.
    PubMed     Abstract available


  138. KIM KH, Kim SH, Park NY, Hyun JW, et al
    Reappraisal of CSF-specific oligoclonal bands in Asia.
    Mult Scler. 2022;28:665-668.
    PubMed     Abstract available


  139. KUHLE J, Daizadeh N, Benkert P, Maceski A, et al
    Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
    Mult Scler. 2022;28:573-582.
    PubMed     Abstract available


  140. BAJRAMI A, Magliozzi R, Pisani AI, Pizzini FB, et al
    Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS.
    Mult Scler. 2022;28:550-560.
    PubMed     Abstract available


  141. VALENTINE TR, Alschuler KN, Ehde DM, Kratz AL, et al
    Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis.
    Mult Scler. 2022;28:620-631.
    PubMed     Abstract available


    March 2022
  142. GASPERI C, Hapfelmeier A, Schneider A, Kuhn KA, et al
    Association of pregnancies with risk of multiple sclerosis.
    Mult Scler. 2022 Mar 18:13524585221080542. doi: 10.1177/13524585221080542.
    PubMed     Abstract available


  143. PORTACCIO E, Pasto L, Razzolini L, Moiola L, et al
    Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
    Mult Scler. 2022 Mar 16:13524585221079598. doi: 10.1177/13524585221079598.
    PubMed     Abstract available


  144. RIEMENSCHNEIDER M, Hvid LG, Ringgaard S, Nygaard MKE, et al
    Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
    Mult Scler. 2022 Mar 16:13524585221079200. doi: 10.1177/13524585221079200.
    PubMed     Abstract available


  145. CARLSON A, McGinley MP
    Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.
    Mult Scler. 2022 Mar 16:13524585221081985. doi: 10.1177/13524585221081985.
    PubMed    


  146. LIANG G, Zhu F, Mirza AI, Bar-Or A, et al
    Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases.
    Mult Scler. 2022 Mar 16:13524585221079533. doi: 10.1177/13524585221079533.
    PubMed     Abstract available


  147. JACOBS BM, Watson C, Marshall C, Noyce A, et al
    No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 16:13524585221075744. doi: 10.1177/13524585221075744.
    PubMed    


  148. DALGAS U, Stenager E, Hvid LG
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: Commentary.
    Mult Scler. 2022 Mar 16:13524585211072702. doi: 10.1177/13524585211072702.
    PubMed    


  149. MOTL RW, Sandroff BM
    Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect-Yes.
    Mult Scler. 2022 Mar 16:13524585211061651. doi: 10.1177/13524585211061651.
    PubMed    


  150. HEESEN C, Rosenkranz SC
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No.
    Mult Scler. 2022 Mar 16:13524585211064968. doi: 10.1177/13524585211064968.
    PubMed    


  151. WENDEL EM, Bertolini A, Kousoulos L, Rauchenzauner M, et al
    Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome.
    Mult Scler. 2022 Mar 14:13524585221081090. doi: 10.1177/13524585221081090.
    PubMed     Abstract available


  152. BSTEH G, Hegen H, Berek K, Altmann P, et al
    Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
    Mult Scler. 2022 Mar 12:13524585221079744. doi: 10.1177/13524585221079744.
    PubMed     Abstract available


  153. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 12:13524585221079044. doi: 10.1177/13524585221079044.
    PubMed    


  154. GARTNER J, Hauser SL, Bar-Or A, Montalban X, et al
    Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
    Mult Scler. 2022 Mar 10:13524585221078825. doi: 10.1177/13524585221078825.
    PubMed     Abstract available


  155. ARNOLD DL, Piani-Meier D, Bar-Or A, Benedict RH, et al
    Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
    Mult Scler. 2022 Mar 9:13524585221076717. doi: 10.1177/13524585221076717.
    PubMed     Abstract available


  156. BEBO BF JR, Allegretta M, Landsman D, Zackowski KM, et al
    Pathways to cures for multiple sclerosis: A research roadmap.
    Mult Scler. 2022;28:331-345.
    PubMed     Abstract available


  157. HAUSER SL, Cross AH, Winthrop K, Wiendl H, et al
    Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
    Mult Scler. 2022 Mar 1:13524585221079731. doi: 10.1177/13524585221079731.
    PubMed     Abstract available


  158. PORTACCIO E, Tudisco L, Pasto L, Razzolini L, et al
    Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.
    Mult Scler. 2022;28:472-479.
    PubMed     Abstract available


  159. VAVASOUR IM, Sun P, Graf C, Yik JT, et al
    Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging.
    Mult Scler. 2022;28:418-428.
    PubMed     Abstract available


    February 2022
  160. TUR C, Dubessy AL, Otero-Romero S, Amato MP, et al
    The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
    Mult Scler. 2022 Feb 23:13524585211069068. doi: 10.1177/13524585211069068.
    PubMed     Abstract available


  161. SHAFIN N, Ismail CAN, Mustafa MZ, Ghani N, et al
    Thematic analysis of multiple sclerosis research by enhanced strategic diagram.
    Mult Scler. 2022 Feb 15:13524585221075542. doi: 10.1177/13524585221075542.
    PubMed     Abstract available



  162. Erratum to "Assessing diagnosis disclosure and concealment in multiple sclerosis: building a framework for moving forward".
    Mult Scler. 2022 Feb 11:13524585221079450. doi: 10.1177/13524585221079450.
    PubMed    


  163. BECK ES, Maranzano J, Luciano NJ, Parvathaneni P, et al
    Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis.
    Mult Scler. 2022 Feb 10:13524585211069167. doi: 10.1177/13524585211069167.
    PubMed     Abstract available


  164. RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Patten S, et al
    Productivity loss among people with early multiple sclerosis: A Canadian study.
    Mult Scler. 2022 Feb 9:13524585211069070. doi: 10.1177/13524585211069070.
    PubMed     Abstract available


  165. O'MAHONY J, Banwell B, Laporte A, Brown A, et al
    The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents.
    Mult Scler. 2022 Feb 7:13524585211061521. doi: 10.1177/13524585211061521.
    PubMed     Abstract available


  166. HOLM HANSEN R, Hojsgaard Chow H, Talbot J, Buhelt S, et al
    Peripheral helper T cells in the pathogenesis of multiple sclerosis.
    Mult Scler. 2022 Feb 3:13524585211067696. doi: 10.1177/13524585211067696.
    PubMed     Abstract available


  167. DOBSON R, Chung K
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary.
    Mult Scler. 2022;28:326-327.
    PubMed    


  168. COYLE PK, Syritsyna O
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Yes.
    Mult Scler. 2022;28:183-185.
    PubMed    


  169. BERMEL RA
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - No.
    Mult Scler. 2022;28:185-187.
    PubMed    


  170. FOX RJ, Tintore M
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Commentary.
    Mult Scler. 2022;28:187-188.
    PubMed    


  171. HILLERT J, Tsai JA, Nouhi M, Glaser A, et al
    A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
    Mult Scler. 2022;28:237-246.
    PubMed     Abstract available


  172. ZHENG Y, Dudman J, Chen JT, Mahajan KR, et al
    Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.
    Mult Scler. 2022;28:198-205.
    PubMed     Abstract available


  173. PFEUFFER S, Rolfes L, Hackert J, Kleinschnitz K, et al
    Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
    Mult Scler. 2022;28:257-268.
    PubMed     Abstract available


    January 2022
  174. LIAO CM, Kuo WY, Kung PT, Chuan CH, et al
    Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan.
    Mult Scler. 2022 Jan 25:13524585211061341. doi: 10.1177/13524585211061341.
    PubMed     Abstract available


  175. NAKAMURA K, Zheng Y, Ontaneda D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yes.
    Mult Scler. 2022 Jan 22:13524585211066313. doi: 10.1177/13524585211066313.
    PubMed    


  176. MUHLAU M
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No.
    Mult Scler. 2022 Jan 22:13524585211063622. doi: 10.1177/13524585211063622.
    PubMed    


  177. ROVIRA A, Pareto D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis - Commentary.
    Mult Scler. 2022 Jan 22:13524585211069363. doi: 10.1177/13524585211069363.
    PubMed    


  178. KEVER A, Riley CS, Leavitt VM
    Diagnosis concealment is associated with psychosocial outcomes in persons with multiple sclerosis.
    Mult Scler. 2022 Jan 16:13524585211070496. doi: 10.1177/13524585211070496.
    PubMed     Abstract available


  179. P MOSS B, Miller DM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward.
    Mult Scler. 2022 Jan 11:13524585211069668. doi: 10.1177/13524585211069668.
    PubMed    


  180. BELVISI D, Canevelli M, Marfia GA, Ferraro E, et al
    Response to "Frailty in multiple sclerosis: A closer look at the deficit accumulation framework".
    Mult Scler. 2022 Jan 8:13524585211068150. doi: 10.1177/13524585211068150.
    PubMed    


  181. ZIAEI A, Lavery AM, Shao XM, Adams C, et al
    Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.
    Mult Scler. 2022 Jan 8:13524585211069926. doi: 10.1177/13524585211069926.
    PubMed     Abstract available


  182. VAN KEMPEN ZL, Hogenboom L, Killestein J
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
    Mult Scler. 2022 Jan 7:13524585211064441. doi: 10.1177/13524585211064441.
    PubMed    


  183. COHEN JA, Bermel RA, Grossman CI, Hersh CM, et al
    Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
    Mult Scler. 2022 Jan 7:13524585211061343. doi: 10.1177/13524585211061343.
    PubMed     Abstract available


  184. THOMPSON AJ, Carroll W, Ciccarelli O, Comi G, et al
    Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.
    Mult Scler. 2022;28:16-28.
    PubMed     Abstract available


  185. COMABELLA M, Clarke MA, Schaedelin S, Tintore M, et al
    CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.
    Mult Scler. 2022;28:71-81.
    PubMed     Abstract available


  186. SIGNORIELLO E, Lus G, Bonavita S, Lanzillo R, et al
    Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
    Mult Scler. 2022;28:93-101.
    PubMed     Abstract available


    December 2021
  187. GAITAN MI, Sanchez M, Farez MF, Fiol MP, et al
    The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina.
    Mult Scler. 2021 Dec 31:13524585211067521. doi: 10.1177/13524585211067521.
    PubMed     Abstract available


  188. BERNARDI G, Biagioli T, Malpassi P, De Michele T, et al
    The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study.
    Mult Scler. 2021 Dec 30:13524585211064121. doi: 10.1177/13524585211064121.
    PubMed     Abstract available


  189. CAVACO S, Ferreira I, Moreira I, Santos E, et al
    Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review.
    Mult Scler. 2021 Dec 30:13524585211066598. doi: 10.1177/13524585211066598.
    PubMed     Abstract available


  190. VAN KEMPEN ZL, Toorop AA, Sellebjerg F, Giovannoni G, et al
    Extended dosing of monoclonal antibodies in multiple sclerosis.
    Mult Scler. 2021 Dec 24:13524585211065711. doi: 10.1177/13524585211065711.
    PubMed     Abstract available


  191. NG HS, Zhu F, Kingwell E, Zhao Y, et al
    Disease-modifying drugs for multiple sclerosis and subsequent health service use.
    Mult Scler. 2021 Dec 24:13524585211063403. doi: 10.1177/13524585211063403.
    PubMed     Abstract available


  192. FERNANDEZ RS, Crivelli L, Pedreira ME, Allegri RF, et al
    Computational basis of decision-making impairment in multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211059308. doi: 10.1177/13524585211059308.
    PubMed     Abstract available


  193. ZANOTTO T, Lynch SG, Hausdorff JM, Sosnoff JJ, et al
    Frailty in multiple sclerosis: A closer look at the deficit accumulation framework.
    Mult Scler. 2021 Dec 21:13524585211061332. doi: 10.1177/13524585211061332.
    PubMed    


  194. ROLFES L, Meuth SG
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
    Mult Scler. 2021 Dec 21:13524585211055593. doi: 10.1177/13524585211055593.
    PubMed    


  195. TOOROP AA, Rispens T, Strijbis EM, van Oosten BW, et al
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211052168. doi: 10.1177/13524585211052168.
    PubMed     Abstract available


  196. JANUEL E, De Seze J, Vermersch P, Maillart E, et al
    Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
    Mult Scler. 2021 Dec 21:13524585211049737. doi: 10.1177/13524585211049737.
    PubMed     Abstract available


  197. COLES AJ, Jones JL, Vermersch P, Traboulsee A, et al
    Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
    Mult Scler. 2021 Dec 9:13524585211061335. doi: 10.1177/13524585211061335.
    PubMed     Abstract available


  198. ROVIRA A, Corral JF, Auger C, Valverde S, et al
    Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients.
    Mult Scler. 2021 Dec 3:13524585211061339. doi: 10.1177/13524585211061339.
    PubMed     Abstract available


  199. LEEKOFF M, Culpepper W, Jin S, Lee-Wilk T, et al
    Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study.
    Mult Scler. 2021 Dec 2:13524585211058361. doi: 10.1177/13524585211058361.
    PubMed     Abstract available


  200. NOURBAKHSH B
    Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
    Mult Scler. 2021;27:2290.
    PubMed    


  201. LEHMANN H, Zveik O, Levin N, Brill L, et al
    Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses.
    Mult Scler. 2021;27:2232-2239.
    PubMed     Abstract available


  202. OH J, Suthiphosuwan S, Sati P, Absinta M, et al
    Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS.
    Mult Scler. 2021;27:2199-2208.
    PubMed     Abstract available


    November 2021
  203. SARKAR P, Redondo J, Hares K, Bailey S, et al
    Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.
    Mult Scler. 2021 Nov 29:13524585211060686. doi: 10.1177/13524585211060686.
    PubMed     Abstract available


  204. OTERO-ROMERO S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, et al
    Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.
    Mult Scler. 2021 Nov 29:13524585211053001. doi: 10.1177/13524585211053001.
    PubMed     Abstract available


  205. KIRA JI, Nakahara J, Sazonov DV, Kurosawa T, et al
    Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
    Mult Scler. 2021 Nov 17:13524585211055934. doi: 10.1177/13524585211055934.
    PubMed     Abstract available


  206. SCHORR EM, Kurz D, Rossi KC, Zhang M, et al
    Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.
    Mult Scler. 2021 Nov 17:13524585211051316. doi: 10.1177/13524585211051316.
    PubMed     Abstract available


  207. MARRIE RA, McKay K
    Administrative data for observational research in multiple sclerosis: Opportunities and challenges.
    Mult Scler. 2021 Nov 17:13524585211055787. doi: 10.1177/13524585211055787.
    PubMed    


  208. MAUBEUGE N, Deloire MS, Brochet B, Charre-Morin J, et al
    Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.
    Mult Scler. 2021 Nov 12:13524585211054006. doi: 10.1177/13524585211054006.
    PubMed     Abstract available


  209. MOUMDJIAN L, Moens B, Van Wijmeersh B, Leman M, et al
    Application of step and beat alignment approaches and its effect on gait in progressive multiple sclerosis with severe cerebellar ataxia: A proof of concept case study.
    Mult Scler. 2021 Nov 2:13524585211054000. doi: 10.1177/13524585211054000.
    PubMed     Abstract available


  210. DAHLKE F, Arnold DL, Aarden P, Ganjgahi H, et al
    Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
    Mult Scler. 2021;27:2062-2076.
    PubMed     Abstract available


    October 2021
  211. MISICKA E, Davis MF, Kim W, Brugger SW, et al
    A higher burden of multiple sclerosis genetic risk confers an earlier onset.
    Mult Scler. 2021 Oct 28:13524585211053155. doi: 10.1177/13524585211053155.
    PubMed     Abstract available


  212. PONCET-MEGEMONT L, Pereira B, Rollot F, Sormani MP, et al
    Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.
    Mult Scler. 2021 Oct 26:13524585211052400. doi: 10.1177/13524585211052400.
    PubMed     Abstract available


  213. BERGAMASCHI R, Montomoli C
    Air pollution is a risk factor for multiple sclerosis - Yes.
    Mult Scler. 2021 Oct 22:13524585211035953. doi: 10.1177/13524585211035953.
    PubMed    


  214. DELGADO-GARCIA G, Corona T
    Air pollution is a risk factor for multiple sclerosis - No.
    Mult Scler. 2021 Oct 22:13524585211026875. doi: 10.1177/13524585211026875.
    PubMed    


  215. SAHRAIAN MA
    Air pollution is a risk factor for multiple sclerosis - Commentary.
    Mult Scler. 2021 Oct 22:13524585211046352. doi: 10.1177/13524585211046352.
    PubMed    


  216. ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
    Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
    Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
    PubMed     Abstract available


  217. UHER T, Havrdova EK, Benkert P, Bergsland N, et al
    Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
    Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
    PubMed     Abstract available


  218. VILLOSLADA P
    Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
    Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.
    PubMed    


  219. WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
    Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
    Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
    PubMed     Abstract available


  220. SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
    Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
    Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
    PubMed     Abstract available


  221. BOSMA AR, Murley C, Aspling J, Hillert J, et al
    Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
    Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
    PubMed     Abstract available


  222. BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
    Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
    Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
    PubMed     Abstract available


  223. GROTHE M, Ellenberger D, von Podewils F, Stahmann A, et al
    Epilepsy as a predictor of disease progression in multiple sclerosis.
    Mult Scler. 2021 Oct 1:13524585211046739. doi: 10.1177/13524585211046739.
    PubMed     Abstract available


  224. SANDROFF BM, Motl RW, Amato MP, Brichetto G, et al
    Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.
    Mult Scler. 2021 Oct 1:13524585211048397. doi: 10.1177/13524585211048397.
    PubMed     Abstract available


  225. BSTEH G, Durauer S, Assar H, Hegen H, et al
    Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
    Mult Scler. 2021 Oct 1:13524585211049391. doi: 10.1177/13524585211049391.
    PubMed     Abstract available


  226. GEORGIEVA ZG, Dffinger R, Kumararatne D, Coles AJ, et al
    Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2021 Oct 1:13524585211046786. doi: 10.1177/13524585211046786.
    PubMed     Abstract available


  227. CAMERON MH, Hildebrand A, Hugos CL, Judd GI, et al
    Free From Falls education and exercise program for reducing falls in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2021 Oct 1:13524585211046898. doi: 10.1177/13524585211046898.
    PubMed     Abstract available


  228. ROBERS MV, Chan C, Vajdi B, Chiong-Rivero H, et al
    Hypertension and hypertension severity in Hispanics/Latinx with MS.
    Mult Scler. 2021;27:1894-1901.
    PubMed     Abstract available


  229. ELKJAER ML, Frisch T, Tonazzolli A, Rottger R, et al
    Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions.
    Mult Scler. 2021;27:1829-1837.
    PubMed     Abstract available


  230. KOCH MW, Mostert JP, Uitdehaag B, Cutter G, et al
    A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
    Mult Scler. 2021;27:1864-1874.
    PubMed     Abstract available


  231. KOCH MW, Metz L, Cutter G
    An enrichment strategy for clinical trials in SPMS.
    Mult Scler. 2021;27:1884-1893.
    PubMed     Abstract available


    September 2021
  232. BUSSAS M, Grahl S, Pongratz V, Berthele A, et al
    Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
    Mult Scler. 2021 Sep 30:13524585211044957. doi: 10.1177/13524585211044957.
    PubMed     Abstract available


  233. KEVER A, Leavitt VM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey.
    Mult Scler. 2021 Sep 9:13524585211037581. doi: 10.1177/13524585211037581.
    PubMed     Abstract available


  234. KRYSKO KM, Anderson A, Singh J, McPolin K, et al
    Risk factors for peripartum depression in women with multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211041108. doi: 10.1177/13524585211041108.
    PubMed     Abstract available


  235. WOJCIK C, Jaworski M 3rd, Dwyer MG, Youngs M, et al
    Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211044672. doi: 10.1177/13524585211044672.
    PubMed     Abstract available


  236. TREMLETT H, Okuda DT, Lebrun-Frenay C
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No.
    Mult Scler. 2021 Sep 8:13524585211035951. doi: 10.1177/13524585211035951.
    PubMed    


  237. GNANAPAVAN S
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Yes.
    Mult Scler. 2021 Sep 8:13524585211040223. doi: 10.1177/13524585211040223.
    PubMed    


  238. MAKHANI N
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Commentary.
    Mult Scler. 2021 Sep 8:13524585211044951. doi: 10.1177/13524585211044951.
    PubMed    


  239. BRADLEY L
    Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
    Mult Scler. 2021 Sep 5:13524585211035737. doi: 10.1177/13524585211035737.
    PubMed     Abstract available


  240. ENZINGER C
    Slowly expanding lesions are a marker of progressive multiple sclerosis - Commentary.
    Mult Scler. 2021 Sep 3:13524585211040225. doi: 10.1177/13524585211040225.
    PubMed    


  241. HARTUNG HP, Meuth SG, Thompson AJ
    Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
    Mult Scler. 2021;27:1473-1476.
    PubMed    


  242. GOLD R, Arnold DL, Bar-Or A, Fox RJ, et al
    Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Mult Scler. 2021 Sep 1:13524585211037909. doi: 10.1177/13524585211037909.
    PubMed     Abstract available


    August 2021
  243. CONWAY DS, Marck CH
    Comorbidities require special attention in minorities with multiple sclerosis.
    Mult Scler. 2021 Aug 27:13524585211037578. doi: 10.1177/13524585211037578.
    PubMed    


  244. BLASCHKE SJ, Ellenberger D, Flachenecker P, Hellwig K, et al
    Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.
    Mult Scler. 2021 Aug 27:13524585211039753. doi: 10.1177/13524585211039753.
    PubMed     Abstract available


  245. COHEN JA, Cameron MH, Goldman MD, Goodman AD, et al
    A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
    Mult Scler. 2021 Aug 27:13524585211035333. doi: 10.1177/13524585211035333.
    PubMed     Abstract available


  246. GUERRA T, Bollo L, Trojano M, Iaffaldano P, et al
    Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
    Mult Scler. 2021 Aug 27:13524585211030214. doi: 10.1177/13524585211030214.
    PubMed     Abstract available


  247. ALONSO R, Galleguillos L
    Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
    Mult Scler. 2021 Aug 27:13524585211039750. doi: 10.1177/13524585211039750.
    PubMed    


  248. ABBADESSA G, Lavorgna L, Treaba CA, Bonavita S, et al
    Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039111. doi: 10.1177/13524585211039111.
    PubMed     Abstract available


  249. BUTLER PAGNOTTI R, Hua LH, Miller JB
    Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039112. doi: 10.1177/13524585211039112.
    PubMed     Abstract available


  250. TILLAUT H, Degremont A, Kerbrat S, Roux J, et al
    Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies.
    Mult Scler. 2021 Aug 19:13524585211035376. doi: 10.1177/13524585211035376.
    PubMed     Abstract available


  251. ROMMER PS, Bsteh G, Berger T, Zettl UK, et al
    SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?
    Mult Scler. 2021 Aug 13:13524585211039128. doi: 10.1177/13524585211039128.
    PubMed    


  252. MARCHESI O, Bonacchi R, Valsasina P, Preziosa P, et al
    Functional and structural MRI correlates of executive functions in multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211033184. doi: 10.1177/13524585211033184.
    PubMed     Abstract available


  253. CLAFLIN SB, Campbell JA, Mason DF, Kalincik T, et al
    The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211035948. doi: 10.1177/13524585211035948.
    PubMed     Abstract available


  254. WEINSTOCK-GUTTMAN B, Bermel R, Cutter G, Freedman MS, et al
    Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
    Mult Scler. 2021 Aug 12:13524585211035740. doi: 10.1177/13524585211035740.
    PubMed     Abstract available


  255. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study.
    Mult Scler. 2021 Aug 11:13524585211034826. doi: 10.1177/13524585211034826.
    PubMed     Abstract available


  256. AYADI N, Oertel FC, Asseyer S, Rust R, et al
    Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2021 Aug 11:13524585211032801. doi: 10.1177/13524585211032801.
    PubMed     Abstract available


  257. ZHENG F, Li Y, Zhuo Z, Duan Y, et al
    Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2021 Aug 11:13524585211032800. doi: 10.1177/13524585211032800.
    PubMed     Abstract available


  258. COMI G, Dadon Y, Sasson N, Steinerman JR, et al
    CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Aug 11:13524585211032803. doi: 10.1177/13524585211032803.
    PubMed     Abstract available


  259. PANDIT L
    Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines.
    Mult Scler. 2021;27:1320-1322.
    PubMed    


  260. KANINIA S, Grammatikos A, Urankar K, Renowden SA, et al
    CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant.
    Mult Scler. 2021;27:1464-1467.
    PubMed     Abstract available


    July 2021
  261. SORMANI MP, Schiavetti I, Landi D, Carmisciano L, et al
    SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
    Mult Scler. 2021 Jul 30:13524585211035318. doi: 10.1177/13524585211035318.
    PubMed     Abstract available


  262. ROTSTEIN D, Maxwell C, Tu K, Gatley J, et al
    High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis.
    Mult Scler. 2021 Jul 30:13524585211031791. doi: 10.1177/13524585211031791.
    PubMed     Abstract available


  263. PITTERI M, Magliozzi R, Nicholas R, Ziccardi S, et al
    Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients.
    Mult Scler. 2021 Jul 30:13524585211032510. doi: 10.1177/13524585211032510.
    PubMed     Abstract available


  264. UHR L, Mateen FJ
    COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey.
    Mult Scler. 2021 Jul 27:13524585211030647. doi: 10.1177/13524585211030647.
    PubMed     Abstract available


  265. LAURSON-DOUBE J, Rijke N, Helme A, Baneke P, et al
    Ethical use of off-label disease-modifying therapies for multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211030207. doi: 10.1177/13524585211030207.
    PubMed     Abstract available


  266. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211031801. doi: 10.1177/13524585211031801.
    PubMed     Abstract available


  267. LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
    Risk of depression in multiple sclerosis across disease-modifying therapies.
    Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
    PubMed     Abstract available


  268. BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
    Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
    PubMed     Abstract available


  269. MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
    A smartphone sensor-based digital outcome assessment of multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
    PubMed     Abstract available


  270. HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
    Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
    Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
    PubMed     Abstract available


  271. WIJERATNE T, Carroll W
    World Brain Day 2021: Global campaign to stop multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.
    PubMed    


  272. HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
    Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
    Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
    PubMed     Abstract available


  273. VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
    Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
    Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
    PubMed     Abstract available


  274. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
    Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
    PubMed     Abstract available


  275. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
    Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
    Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
    PubMed     Abstract available


  276. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
    Performance validity in outpatients with multiple sclerosis and cognitive complaints.
    Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
    PubMed     Abstract available


  277. ESHAGHI A
    Towards an objective classification of multiple sclerosis.
    Mult Scler. 2021;27:1151-1152.
    PubMed    


  278. CALDITO NG, O'Leary S, Stuve O
    Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Mult Scler. 2021;27:1306-1308.
    PubMed     Abstract available


  279. MARRIE RA, Patel R, Bernstein CN, Bolton JM, et al
    Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.
    Mult Scler. 2021;27:1284-1292.
    PubMed     Abstract available


  280. CENCIONI MT, Ali R, Nicholas R, Muraro PA, et al
    Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS.
    Mult Scler. 2021;27:1187-1197.
    PubMed     Abstract available


    June 2021
  281. SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
    Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
    PubMed     Abstract available


  282. MIZELL R, Chen H, Lambe J, Saidha S, et al
    Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
    Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
    PubMed     Abstract available


  283. BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
    Altered anterior default mode network dynamics in progressive multiple sclerosis.
    Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
    PubMed     Abstract available


  284. HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
    Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
    Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
    PubMed     Abstract available


  285. WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
    High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
    Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
    PubMed     Abstract available


  286. VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
    Acute and chronic synaptic pathology in multiple sclerosis gray matter.
    Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
    PubMed     Abstract available


  287. CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
    Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
    Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
    PubMed     Abstract available


  288. SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
    Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
    Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
    PubMed     Abstract available


  289. KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
    The timed 25-foot walk in a large cohort of multiple sclerosis patients.
    Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
    PubMed     Abstract available


  290. GARJANI A, Hunter R, Law GR, Middleton RM, et al
    Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
    Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
    PubMed     Abstract available


  291. SCHMIERER K, Giovannoni G
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Commentary.
    Mult Scler. 2021;27:1006-1007.
    PubMed    


  292. SCALFARI A
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes.
    Mult Scler. 2021;27:1002-1004.
    PubMed    


  293. CROSS AH, Naismith RT
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No.
    Mult Scler. 2021;27:1004-1005.
    PubMed    


  294. ZACKOWSKI KM, Freeman J, Brichetto G, Centonze D, et al
    Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance.
    Mult Scler. 2021;27:989-1001.
    PubMed     Abstract available


  295. MORROW SA, Conway D, Fuchs T, Wojcik C, et al
    Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
    Mult Scler. 2021;27:1077-1087.
    PubMed     Abstract available


  296. NAYAK S, Sechi E, Flanagan EP, Messina S, et al
    Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
    Mult Scler. 2021;27:1037-1045.
    PubMed     Abstract available


  297. REDER AT
    Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS.
    Mult Scler. 2021;27:1008-1013.
    PubMed     Abstract available


    May 2021
  298. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
    Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
    PubMed     Abstract available


  299. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
    Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
    PubMed     Abstract available


  300. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
    Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
    Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
    PubMed     Abstract available


  301. MCMURRAN CE
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
    Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
    PubMed    


  302. CALVO-BARREIRO L, Clerico M, Espejo C
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
    Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
    PubMed    


  303. HOHLFELD R
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
    Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
    PubMed    


  304. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
    Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
    Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
    PubMed     Abstract available


  305. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
    Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
    Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
    PubMed     Abstract available


  306. DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
    Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
    PubMed     Abstract available


  307. WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
    Staging and stratifying cognitive dysfunction in multiple sclerosis.
    Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
    PubMed     Abstract available


  308. BROWNLEE WJ, Solomon AJ
    Misdiagnosis of multiple sclerosis: Time for action.
    Mult Scler. 2021;27:805-806.
    PubMed    


  309. LONGBRAKE EE, Mao-Draayer Y, Cascione M, Zielinski T, et al
    Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
    Mult Scler. 2021;27:883-894.
    PubMed     Abstract available


  310. CAI MT, Zheng Y, Shen CH, Yang F, et al
    Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
    Mult Scler. 2021;27:871-882.
    PubMed     Abstract available


  311. KASSA RM, Sechi E, Flanagan EP, Kaufmann TJ, et al
    Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.
    Mult Scler. 2021;27:895-902.
    PubMed     Abstract available


    April 2021
  312. HOLLEN C, Rice J, Park M, Yadav V, et al
    Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
    Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
    PubMed     Abstract available


  313. GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
    The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
    Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
    PubMed     Abstract available


  314. VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
    Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
    Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
    PubMed     Abstract available


  315. KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
    Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
    Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
    PubMed     Abstract available


  316. HARRISON AM, Safari R, Mercer T, Picariello F, et al
    Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
    Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
    PubMed     Abstract available


  317. ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
    Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
    Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
    PubMed     Abstract available


  318. ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
    Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
    Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
    PubMed     Abstract available


  319. PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
    Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
    Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
    PubMed     Abstract available


  320. CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
    Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
    Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
    PubMed     Abstract available


  321. CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
    Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
    PubMed     Abstract available


  322. FLEMING KM, Coote SB, Herring MP
    Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
    Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
    PubMed     Abstract available


  323. SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
    Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
    Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
    PubMed     Abstract available


  324. D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
    Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
    Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
    PubMed     Abstract available


  325. CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
    Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
    Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
    PubMed     Abstract available


  326. COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
    Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
    Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
    PubMed     Abstract available


  327. ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
    COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
    PubMed     Abstract available


  328. TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
    A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
    PubMed     Abstract available


  329. BESSING B, Honan CA, van der Mei I, Taylor BV, et al
    Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
    Mult Scler. 2021;27:767-777.
    PubMed     Abstract available


  330. VAN DAM M, Hulst HE, Schoonheim MM
    Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
    Mult Scler. 2021;27:491-493.
    PubMed    


  331. MANCINELLI CR, Scarpazza C, Cordioli C, De Rossi N, et al
    Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mult Scler. 2021;27:790-794.
    PubMed     Abstract available


  332. BIGAUT K, Fabacher T, Kremer L, Ongagna JC, et al
    Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
    Mult Scler. 2021;27:729-741.
    PubMed     Abstract available


  333. KUNCHOK A, Lechner-Scott J, Granella F, Trojano M, et al
    Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
    Mult Scler. 2021;27:695-705.
    PubMed     Abstract available


  334. SECHI E, Messina S, Keegan BM, Buciuc M, et al
    Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
    Mult Scler. 2021;27:667-673.
    PubMed     Abstract available


  335. DATTA P, Ciplea AI, Rewers-Felkins K, Baker T, et al
    Cladribine transfer into human milk: A case report.
    Mult Scler. 2021;27:799-801.
    PubMed     Abstract available


    March 2021
  336. HOWLETT-PRIETO Q, Feng X, Kramer JF, Kramer KJ, et al
    Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis.
    Mult Scler. 2021 Mar 30:13524585211003301. doi: 10.1177/13524585211003301.
    PubMed     Abstract available


  337. THEODORSDOTTIR A, Debrabant B, Magyari M, Kant M, et al
    Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
    Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291.
    PubMed     Abstract available


  338. CREE BA, Cohen JA, Reder AT, Tomic D, et al
    Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
    Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177/13524585211000280.
    PubMed     Abstract available


  339. PORTACCIO E, Fonderico M, Hemmer B, Derfuss T, et al
    Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
    Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177/13524585211005339.
    PubMed     Abstract available


  340. LEE LE, Vavasour IM, Dvorak A, Liu H, et al
    Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
    Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177/13524585211001780.
    PubMed     Abstract available


  341. HARROUD A, Mitchell RE, Richardson TG, Morris JA, et al
    Childhood obesity and multiple sclerosis: A Mendelian randomization study.
    Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177/13524585211001781.
    PubMed     Abstract available


  342. BRIGGS FB, Krill D, Hill E, Conway DS, et al
    Age of hypertension onset in multiple sclerosis patients.
    Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
    PubMed     Abstract available


  343. MASSAROTTI C, Sbragia E, Boffa G, Vercelli C, et al
    Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616.
    PubMed     Abstract available


  344. SCHOONHEIM MM, Douw L, Broeders TA, Eijlers AJ, et al
    The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis.
    Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177/1352458521999274.
    PubMed     Abstract available


  345. MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
    Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
    Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
    PubMed     Abstract available


  346. LORSCHEIDER J
    When does a heap become a heap?
    Mult Scler. 2021;27:329-330.
    PubMed    


  347. BUTZKUEVEN H, Trojano M, Kappos L, Spelman T, et al
    Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP).
    Mult Scler. 2021;27:410-419.
    PubMed     Abstract available


    February 2021
  348. SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
    Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
    PubMed     Abstract available


  349. FOX RJ, Raska P, Barro C, Karafa M, et al
    Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
    PubMed     Abstract available


  350. COPETTI M, Liu D
    Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
    Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
    PubMed    


  351. HARROUD A, Manousaki D, Butler-Laporte G, Mitchell RE, et al
    The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis.
    Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484.
    PubMed     Abstract available


  352. BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
    Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
    Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
    PubMed     Abstract available


  353. LEMA DOPICO A, Choi S, Hua J, Li X, et al
    Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability.
    Mult Scler. 2021 Feb 18:1352458521994556. doi: 10.1177/1352458521994556.
    PubMed     Abstract available


  354. HARROUD A, Marrie RA, Fitzgerald KC, Salter A, et al
    Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521993075. doi: 10.1177/1352458521993075.
    PubMed     Abstract available


  355. BESSING B, Hussain MA, Claflin SB, Chen J, et al
    Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521994557. doi: 10.1177/1352458521994557.
    PubMed     Abstract available


  356. BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
    Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
    Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
    PubMed     Abstract available


  357. MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
    The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
    Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
    PubMed     Abstract available


  358. VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
    Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
    PubMed     Abstract available


  359. KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
    Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
    PubMed     Abstract available


  360. DAS J, Snowden JA, Burman J, Freedman MS, et al
    Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
    PubMed     Abstract available



  361. Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis.
    Mult Scler. 2021 Feb 2:1352458520978354. doi: 10.1177/1352458520978354.
    PubMed     Abstract available


  362. NYIRENDA MH, Fadda G, Healy LM, Mexhitaj I, et al
    Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
    Mult Scler. 2021 Feb 1:1352458521989090. doi: 10.1177/1352458521989090.
    PubMed     Abstract available


  363. YEH EA
    Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
    Mult Scler. 2021;27:165-166.
    PubMed    


  364. SALTER A, Stahmann A, Ellenberger D, Fneish F, et al
    Data harmonization for collaborative research among MS registries: A case study in employment.
    Mult Scler. 2021;27:281-289.
    PubMed     Abstract available


    January 2021
  365. MANOUCHEHRINIA A, Kingwell E, Zhu F, Tremlett H, et al
    A multiple sclerosis disease progression measure based on cumulative disability.
    Mult Scler. 2021 Jan 25:1352458520988632. doi: 10.1177/1352458520988632.
    PubMed     Abstract available


  366. JALUSIC KO, Ellenberger D, Rommer P, Stahmann A, et al
    Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
    Mult Scler. 2021 Jan 20:1352458520985118. doi: 10.1177/1352458520985118.
    PubMed     Abstract available


  367. BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
    An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
    Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
    PubMed     Abstract available


  368. ROOS I, Leray E, Frascoli F, Casey R, et al
    Determinants of therapeutic lag in multiple sclerosis.
    Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.
    PubMed     Abstract available


  369. FITZGERALD KC, Damian A, Conway D, Mowry EM, et al
    Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.
    Mult Scler. 2021 Jan 8:1352458520984746. doi: 10.1177/1352458520984746.
    PubMed     Abstract available


  370. GONZALEZ-ESCAMILLA G, Groppa S
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - No.
    Mult Scler. 2021 Jan 6:1352458520969662. doi: 10.1177/1352458520969662.
    PubMed    


  371. SATI P, Reich DS
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers - Commentary.
    Mult Scler. 2021 Jan 6:1352458520981738. doi: 10.1177/1352458520981738.
    PubMed    


  372. LOUAPRE C, Beigneux Y
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - Yes.
    Mult Scler. 2021 Jan 6:1352458520972270. doi: 10.1177/1352458520972270.
    PubMed    


  373. ROLLOT F, Casey R, Leray E, Debouverie M, et al
    Cumulative effects of therapies on disability in relapsing multiple sclerosis.
    Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
    PubMed     Abstract available


  374. MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
    Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
    Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
    PubMed     Abstract available


  375. AMATO MP, Portaccio E, De Meo E
    Understanding the pathophysiology of cognitive changes in MS: A step forward.
    Mult Scler. 2021;27:4-5.
    PubMed    


  376. BISTROM M, Hultdin J, Sundstrom P
    Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
    Mult Scler. 2021;27:161-162.
    PubMed    


  377. AL-ARAJI S, Ciccarelli O
    A possible case of serum sickness after ocrelizumab infusion - Commentary.
    Mult Scler. 2021;27:158-159.
    PubMed     Abstract available


  378. LIBERTINOVA J, Meluzinova E, Nema E, Rockova P, et al
    Elevated D-dimer as an immediate response to alemtuzumab treatment.
    Mult Scler. 2021;27:151-154.
    PubMed     Abstract available


  379. ZHANG J, Giorgio A, Vinciguerra C, Stromillo ML, et al
    Gray matter atrophy cannot be fully explained by white matter damage in patients with MS.
    Mult Scler. 2021;27:39-51.
    PubMed     Abstract available


  380. GEORGE IC, El Mendili MM, Inglese M, Azevedo CJ, et al
    Cerebellar volume loss in radiologically isolated syndrome.
    Mult Scler. 2021;27:130-133.
    PubMed     Abstract available


    December 2020
  381. NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
    Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
    Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
    PubMed     Abstract available


  382. GALLO A, Bisecco A
    Psychological resilience explains functional variability across people with multiple sclerosis - Commentary.
    Mult Scler. 2020 Dec 17:1352458520978213. doi: 10.1177/1352458520978213.
    PubMed    


  383. LEAVITT VM, Kever A
    Psychological resilience explains functional variability across people with multiple sclerosis - Yes.
    Mult Scler. 2020 Dec 17:1352458520972263. doi: 10.1177/1352458520972263.
    PubMed    


  384. PLOUGHMAN M
    Psychological resilience explains functional variability across people with multiple sclerosis - No.
    Mult Scler. 2020 Dec 17:1352458520973633. doi: 10.1177/1352458520973633.
    PubMed    


  385. COMABELLA M, Deutschmann C, Midaglia L, Schierack P, et al
    Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
    Mult Scler. 2020 Dec 17:1352458520980141. doi: 10.1177/1352458520980141.
    PubMed     Abstract available


  386. HYLAND MH, Robb JF
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Yes.
    Mult Scler. 2020 Dec 16:1352458520973640. doi: 10.1177/1352458520973640.
    PubMed    


  387. MOCCIA M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No.
    Mult Scler. 2020 Dec 16:1352458520968815. doi: 10.1177/1352458520968815.
    PubMed    


  388. D'HAESELEER M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Commentary.
    Mult Scler. 2020 Dec 16:1352458520979303. doi: 10.1177/1352458520979303.
    PubMed    


  389. CALABRESI PA, Arnold DL, Sangurdekar D, Singh CM, et al
    Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Mult Scler. 2020 Dec 14:1352458520972573. doi: 10.1177/1352458520972573.
    PubMed     Abstract available


  390. FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
    Serum ceramide levels are altered in multiple sclerosis.
    Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
    PubMed     Abstract available


  391. CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
    Depression in multiple sclerosis across the adult lifespan.
    Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
    PubMed     Abstract available


  392. TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
    Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
    Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
    PubMed     Abstract available


  393. NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
    Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
    Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
    PubMed     Abstract available


  394. JACOBS BM, Smets I, Giovannoni G, Noyce A, et al
    Regarding: Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520969941. doi: 10.1177/1352458520969941.
    PubMed    


  395. BRIGGS F
    Response to Jacobs et al, Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520977027. doi: 10.1177/1352458520977027.
    PubMed    


  396. KOUBIYR I, Deloire M, Brochet B, Besson P, et al
    Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis.
    Mult Scler. 2020 Dec 7:1352458520971807. doi: 10.1177/1352458520971807.
    PubMed     Abstract available


  397. VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
    Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
    Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
    PubMed     Abstract available


  398. RAMANUJAM R, Zhu F, Fink K, Karrenbauer VD, et al
    Accurate classification of secondary progression in multiple sclerosis using a decision tree.
    Mult Scler. 2020 Dec 2:1352458520975323. doi: 10.1177/1352458520975323.
    PubMed     Abstract available


  399. SHAH S
    Real-world evidence: One tweet at a time.
    Mult Scler. 2020;26:1965-1966.
    PubMed    


  400. COETZEE T, Thompson AJ
    Atlas of MS 2020: Informing global policy change.
    Mult Scler. 2020;26:1807-1808.
    PubMed    


  401. PILUTTI LA, Fakolade A
    Rehabilitation should be prescribed acutely in motor relapses - Commentary.
    Mult Scler. 2020;26:1825-1827.
    PubMed    


    November 2020
  402. STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
    Youth with multiple sclerosis have low levels of fitness.
    Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
    PubMed     Abstract available


  403. ROMEO AR, Rowles WM, Schleimer ES, Barba P, et al
    An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
    Mult Scler. 2020 Nov 25:1352458520968814. doi: 10.1177/1352458520968814.
    PubMed     Abstract available


  404. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
    Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
    PubMed     Abstract available


  405. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
    PubMed     Abstract available


  406. IAFFALDANO P, Lucisano G, Patti F, Brescia Morra V, et al
    Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
    Mult Scler. 2020 Nov 19:1352458520974366. doi: 10.1177/1352458520974366.
    PubMed     Abstract available


  407. LARONI A, Schiavetti I, Sormani MP, Uccelli A, et al
    COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
    Mult Scler. 2020 Nov 18:1352458520971817. doi: 10.1177/1352458520971817.
    PubMed     Abstract available


  408. CREE BA, Magnusson B, Rouyrre N, Fox RJ, et al
    Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Nov 18:1352458520971819. doi: 10.1177/1352458520971819.
    PubMed     Abstract available


  409. GLUKHOVSKY L, Kurz D, Brandstadter R, Leavitt VM, et al
    Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments.
    Mult Scler. 2020 Nov 16:1352458520958359. doi: 10.1177/1352458520958359.
    PubMed     Abstract available


  410. PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
    Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
    PubMed     Abstract available


  411. HEITMANN H, Andlauer TFM, Korn T, Muhlau M, et al
    Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.
    Mult Scler. 2020 Nov 12:1352458520972279. doi: 10.1177/1352458520972279.
    PubMed     Abstract available


  412. SACCO R, Braga A, Disanto G, Digesu GA, et al
    Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
    Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
    PubMed     Abstract available


  413. KARIM ME, Pellegrini F, Platt RW, Simoneau G, et al
    The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.
    Mult Scler. 2020 Nov 12:1352458520972557. doi: 10.1177/1352458520972557.
    PubMed     Abstract available


  414. AVILA M, Okai A, Thakolwiboon S, O'Bryan C, et al
    The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study.
    Mult Scler. 2020 Nov 12:1352458520971822. doi: 10.1177/1352458520971822.
    PubMed     Abstract available


  415. WALTON C, King R, Rechtman L, Kaye W, et al
    Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
    Mult Scler. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.
    PubMed     Abstract available


  416. HEDSTROM AK, Olsson T, Alfredsson L
    Cotinine as a measure of smoking in observational studies of multiple sclerosis.
    Mult Scler. 2020 Nov 10:1352458520968803. doi: 10.1177/1352458520968803.
    PubMed     Abstract available


  417. LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
    Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
    Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
    PubMed     Abstract available


  418. BUYUKTURKOGLU K, Zeng D, Bharadwaj S, Tozlu C, et al
    Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.
    Mult Scler. 2020 Nov 4:1352458520958362. doi: 10.1177/1352458520958362.
    PubMed     Abstract available


    October 2020
  419. LOZINSKI BM, Yong VW
    Exercise and the brain in multiple sclerosis.
    Mult Scler. 2020 Oct 30:1352458520969099. doi: 10.1177/1352458520969099.
    PubMed     Abstract available


  420. AFZAL HMR, Luo S, Ramadan S, Lechner-Scott J, et al
    The emerging role of artificial intelligence in multiple sclerosis imaging.
    Mult Scler. 2020 Oct 28:1352458520966298. doi: 10.1177/1352458520966298.
    PubMed     Abstract available


  421. PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
    Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
    Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
    PubMed     Abstract available


  422. STRIK M, Chard DT, Dekker I, Meijer KA, et al
    Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
    Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
    PubMed     Abstract available


  423. KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
    Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
    Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
    PubMed     Abstract available


  424. TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
    Parietal dysfunctional connectivity in depression in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
    PubMed    


  425. JAEGER S, Paul F, Finke C
    Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
    PubMed    


  426. BERMEL RA, Fedler JK, Kaiser P, Novalis C, et al
    Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2020 Oct 15:1352458520964409. doi: 10.1177/1352458520964409.
    PubMed     Abstract available


  427. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
    PubMed     Abstract available


  428. CASTELLI L, Quartuccio ME, Ruggieri S, De Giglio L, et al
    'Posture second' strategy predicts disability progression in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963926. doi: 10.1177/1352458520963926.
    PubMed     Abstract available


  429. VEREB D, Toth E, Bozsik B, Kiraly A, et al
    Altered brain network function during attention-modulated visual processing in multiple sclerosis.
    Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
    PubMed     Abstract available


  430. LANGER-GOULD A, Black LJ, Waubant E, Smith JB, et al
    Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility.
    Mult Scler. 2020;26:1476-1485.
    PubMed     Abstract available


  431. CHEN J, Taylor B, Winzenberg T, Palmer AJ, et al
    Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis.
    Mult Scler. 2020;26:1550-1559.
    PubMed     Abstract available


  432. HULST HE, Penner IK
    Cognition and its relation to brain health in patients with MS.
    Mult Scler. 2020;26:1611-1613.
    PubMed    


  433. HOBART J, Giovannoni G
    Cognition and its relation to brain health in patients with MS: Response to letter.
    Mult Scler. 2020;26:1613-1614.
    PubMed    


  434. AZEVEDO CJ, Zamvil SS
    New cases of vasculitis after alemtuzumab.
    Mult Scler. 2020;26:1606-1608.
    PubMed    


    September 2020
  435. PISA M, Chieffo R, Congiu M, Dalla Costa G, et al
    Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520960374. doi: 10.1177/1352458520960374.
    PubMed     Abstract available


  436. FERRE L, Mogavero A, Clarelli F, Moiola L, et al
    Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
    PubMed     Abstract available


  437. BOESEN MS, Blinkenberg M, Thygesen LC, Eriksson F, et al
    School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.
    Mult Scler. 2020 Sep 25:1352458520959673. doi: 10.1177/1352458520959673.
    PubMed     Abstract available


  438. YAM C, Jokubaitis V, Hellwig K, Dobson R, et al
    MS, pregnancy and COVID-19.
    Mult Scler. 2020;26:1137-1146.
    PubMed     Abstract available


  439. MECA-LALLANA V
    COVID-19 will change MS care forever - Yes.
    Mult Scler. 2020;26:1147-1148.
    PubMed    


  440. PREZIOSA P, Rocca MA, Filippi M
    COVID-19 will change MS care forever - No.
    Mult Scler. 2020;26:1149-1151.
    PubMed    


    August 2020
  441. ABBOUD H
    Iatrogenic demyelinating disorders: New insights, new culprits.
    Mult Scler. 2020;26:1129-1130.
    PubMed    


    June 2020

  442. Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis.
    Mult Scler. 2020 Jun 26:1352458520924594. doi: 10.1177/1352458520924594.
    PubMed     Abstract available


  443. RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
    Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
    Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
    PubMed     Abstract available


    May 2020
  444. BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
    Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
    Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
    PubMed    


    March 2020
  445. SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
    Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
    Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
    PubMed     Abstract available


  446. LEITE MI, Sato DK
    MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
    Mult Scler. 2020;26:272-274.
    PubMed    


  447. COBO-CALVO A, Marignier R
    MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
    Mult Scler. 2020;26:274-276.
    PubMed    


  448. DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
    Spontaneous multiple cervical artery dissections after alemtuzumab.
    Mult Scler. 2020;26:381-383.
    PubMed     Abstract available


  449. CHIARAVALLOTI ND, Moore NB, DeLuca J
    The efficacy of the modified Story Memory Technique in progressive MS.
    Mult Scler. 2020;26:354-362.
    PubMed     Abstract available


    February 2020
  450. MCKEON A, Zekeridou A
    Autoimmune encephalitis management: MS centers and beyond.
    Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
    PubMed     Abstract available


  451. THOMPSON AJ, Cohen JA, Kim HJ, Geurts J, et al
    MSJ 2020 - Editorial comment.
    Mult Scler. 2020;26:134.
    PubMed    


  452. LUBLIN F
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Commentary.
    Mult Scler. 2020;26:163-164.
    PubMed    


  453. SORMANI MP
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.
    Mult Scler. 2020;26:161-162.
    PubMed    


  454. KALINCIK T
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
    Mult Scler. 2020;26:159-161.
    PubMed    


    January 2020
  455. WARNKE C, Hartung HP
    Big data in MS-What can we learn from large international observational studies such as MSBase?
    Mult Scler. 2020;26:4-5.
    PubMed    


  456. REDDEL SW
    Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.
    Mult Scler. 2020;26:126-127.
    PubMed    


  457. VUKUSIC S, Casey R, Rollot F, Brochet B, et al
    Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.
    Mult Scler. 2020;26:118-122.
    PubMed     Abstract available


  458. MELI R, Roccatagliata L, Capello E, Bruschi N, et al
    Ecological impact of isolated cognitive relapses in MS.
    Mult Scler. 2020;26:114-117.
    PubMed     Abstract available


    November 2019
  459. COMI G, Alroughani R, Boster AL, Bass AD, et al
    Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
    Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
    PubMed     Abstract available


  460. BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
    Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
    PubMed     Abstract available


    June 2019
  461. GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
    T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
    Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
    PubMed     Abstract available


    March 2019
  462. MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
    Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
    Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
    PubMed     Abstract available


    February 2019
  463. CUKER A, Bass AD, Nadj C, Agius MA, et al
    Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
    Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: